The disclosure relates to a therapeutic composition for treating L. monocytogenese infection or L. monocytogenese colonization, the composition including at least one, at least two, at least three, or all of an isolated C. saccharogumia bacteria, an isolated C. ramosum bacteria, an isolated C. hathewayi bacteria, and/or an isolated B. producta bacteria in a formulation suitable for administration to a subject. The disclosure further provides similar compositions lacking an isolated C. saccharogumia bacteria. The disclosure additionally provides methods of treating L. monocytogenes infection or colonization using such compositions.
